NanoViricides Advances Measles Drug Amid Rising Cases

NanoViricides, Inc., a company at the forefront in antiviral therapies, is moving its investigational Measles drug, NV-387, towards clinical trials. The drug has shown promising efficacy in a mouse model, although not yet FDA-approved for treatment. Recent data indicates a troubling rise in Measles cases in the USA, with 5,164 confirmed cases, leading to several hospitalizations and deaths. Only four states reported no cases in 2026.

The current resurgence challenges previous elimination statuses, underscoring an urgent need for effective treatments. NV-387, also under trial for Ebola and Mpox, has gained a "Rare Pediatric Disease Drug" designation, potentially unlocking various FDA incentives. As vaccine hesitancy grows and breakthrough cases occur, the demand for antiviral drugs like NV-387 increases, highlighting unmet medical needs in combating Measles outbreaks.